Factors Influencing Residual Glandular Breast Tissue after Risk-Reducing Mastectomy in Genetically Predisposed Individuals Detected by MRI Mammography.
Germline heterozygous exons 8–11 pathogenic BARD1 gene deletion reported for the first time in a family with suspicion of a hereditary colorectal cancer syndrome: more than an incidental finding?
Carrera S, Rodríguez-Martínez AB, Garin I, Sarasola E, Martínez C, Maortua H, Callejo A, Ruiz de Lobera A, Muñoz A, Miñambres N, Jiménez-Labaig P.
Hered Cancer Clin Pract. 2023 Jan 28;21(1):2. doi: 10.1186/s13053-023-00246-4.
Oncologist knowledge of cost of genetic testing. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
Weiner S, Austin SE, Carr G, Kidwell KM, Resnicow K, Martinez Stoffel E, Griggs J.
Fam Cancer. [P-23: Research Categories» Delivery of Care and Alternative Models.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
Decreased time from diagnosis to referral of PDAC patients: a quality improvement effort. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
Cohen SA, Doran W, Harshbarger C, Nixon DM, Lichtenberg E, Cantafio A.
Fam Cancer. [P-24: Research Categories» Delivery of Care and Alternative Models.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
Pairing tumor testing with germline sequencing increases the number of pathogenic germline variants identified. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
Germline heterozygous exons 8–11 pathogenic BARD1 gene deletion reported for the first time in a family with suspicion of a hereditary colorectal cancer syndrome: more than an incidental finding?
Carrera S, Rodríguez-Martínez AB, Garin I, Sarasola E, Martínez C, Maortua H, Callejo A, Ruiz de Lobera A, Muñoz A, Miñambres N, Jiménez-Labaig P.
Hered Cancer Clin Pract. 2023 Jan 28;21(1):2. doi: 10.1186/s13053-023-00246-4.
Oncologist knowledge of cost of genetic testing. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
Weiner S, Austin SE, Carr G, Kidwell KM, Resnicow K, Martinez Stoffel E, Griggs J.
Fam Cancer. [P-23: Research Categories» Delivery of Care and Alternative Models.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
Decreased time from diagnosis to referral of PDAC patients: a quality improvement effort. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
Cohen SA, Doran W, Harshbarger C, Nixon DM, Lichtenberg E, Cantafio A.
Fam Cancer. [P-24: Research Categories» Delivery of Care and Alternative Models.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
Pairing tumor testing with germline sequencing increases the number of pathogenic germline variants identified. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women.
Figlioli G, Billaud A, Ahearn TU, Antonenkova NN, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Blok MJ, Bogdanova NV, Bonanni B, Burwinkel B, Camp NJ, Campbell A, Castelao JE, Cessna MH, Chanock SJ; NBCS Collaborators; Czene K, Devilee P, Dörk T, Engel C, Eriksson M, Fasching PA, Figueroa JD, Gabrielson M, Gago-Dominguez M, García-Closas M, González-Neira A, Grassmann F, Guénel P, Gündert M, Hadjisavvas A, Hahnen E, Hall P, Hamann U, Harrington PA, He W, Hillemanns P, Hollestelle A, Hooning MJ, Hoppe R, Howell A, Humphreys K; KConFab Investigators; Jager A, Jakubowska A, Khusnutdinova EK, Ko YD, Kristensen VN, Lindblom A, Lissowska J, Lubiński J, Mannermaa A, Manoukian S, Margolin S, Mavroudis D, Newman WG, Obi N, Panayiotidis MI, Rashid MU, Rhenius V, Rookus MA, Saloustros E, Sawyer EJ, Schmutzler RK, Shah M, Sironen R, Southey MC, Suvanto M, Tollenaar RAEM, Tomlinson I, Truong T, van der Kolk LE, van Veen EM, Wappenschmidt B, Yang XR, Bolla MK, Dennis J, Dunning AM, Easton DF, Lush M, Michailidou K, Pharoah PDP, Wang Q, Adank MA, Schmidt MK, Andrulis IL, Chang-Claude J, Nevanlinna H, Chenevix-Trench G, Evans DG, Milne RL, Radice P, Peterlongo P.
Eur J Hum Genet. 2023 Jan 27. doi: 10.1038/s41431-022-01257-w. Epub ahead of print.
LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma.
Sato S, Gillette M, de Santiago PR, Kuhn E, Burgess M, Doucette K, Feng Y, Mendez-Dorantes C, Ippoliti PJ, Hobday S, Mitchell MA, Doberstein K, Gysler SM, Hirsch MS, Schwartz L, Birrer MJ, Skates SJ, Burns KH, Carr SA, Drapkin R.
Sci Rep. 2023 Jan 27;13(1):1537. doi: 10.1038/s41598-023-28840-5.
Innovative approaches to expanding cancer genetic testing in Michigan (project might). [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
Stoffel EM, Austin S, Koeppe E, Hanson EN, Delacroix E, Rizzo E, Griggs JJ, Resnicow K.
Fam Cancer. [P-17: Research Categories» Delivery of Care and Alternative Models.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
Implementation of a multi modal best practice bundle to improve genetic testing referral for pancreatic cancer patients. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
Blazey M, Lee T, Hendershot A, Bartell N, Marino D.
Fam Cancer. [P-20: Research Categories» Delivery of Care and Alternative Models.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
Performance of INHERET® risk assessment tool for identifying pathogenic germline variants among individuals referred for cancer genetics evaluation. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
Henry ML, Pialtos K, Fry S, Koeppe E, Osborne J, Cook A, Hulswitt B, Milliron KJ, Merajver S, Stoffel E.
Fam Cancer. [P-21: Research Categories» Delivery of Care and Alternative Models.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
Attitudes about sharing genetic test results in families with hereditary cancer syndromes. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
Guivatchian E, Koeppe E, Stoffel EM.
Fam Cancer. [P-22: Research Categories » Other.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
PARP inhibition utilized in combination therapy with Olaparib-Temozolomide to achieve disease stabilization in a rare case of BRCA1-mutant, metastatic myxopapillary ependymoma.
Mahalingam P, Smith S, Lopez J, Sharma RK, Millard T, Thway K, Fisher C, Reardon DA, Jones R, Nicholson AG, Cunningham D, Welsh L, Sharma B.
Rare Tumors. 2023 Jan 19;15:20363613231152333. doi: 10.1177/20363613231152333.
Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma.
Debbabi I, Vacher S, Neuzillet C, Cros J, Revillon F, Petitalot A, Turpin A, Antonio S, Girard E, Dupain C, Kamal M, Hammel P, Bièche I, Masliah-Planchon J, Caputo SM.
Ther Adv Med Oncol. 2023 Jan 18;15:17588359221146132. doi: 10.1177/17588359221146132.
Disparities in the uptake of cascade genetic testing among family members of mutation-positive lynch and HBOC syndrome patients. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
Namey E, Dudley B, Horton C, Carraway C, Zhou J, Hatton W, Komala T, Milliard C, Namey T, Karloski E, Brand R.
Fam Cancer. [O-05: Research Categories» Lynch syndrome.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
Actionable pathogenic germline variants discovered by panel-based hereditary cancer testing in families with previously identified pathogenic variants. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
Neumann C, Mcsweeny M, Rainey K, Campbell H, Nguyen C, Hall M.
Fam Cancer. [P-13: Research Categories » Counseling, Behavioral Health, Psychosocial, and Survivorship.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
Efficacy and safety of treatment regimens for metastatic, locally advanced, or recurrent breast cancer patients with breast cancer susceptibility genes 1 or 2 mutations: a network meta-analysis.
Zhu Y, Li Y, Liu W, Zhou R, Tse SL, Wang Y, Li W.
Front Oncol. 2023 Jan 24;13:1080297. doi: 10.3389/fonc..2023.1080297.
Cultural adaptations to a telephone genetic counseling protocol and booklet for Latina breast cancer survivors at risk for hereditary breast and ovarian cancer.
Long-Term Non-Cancer Risks in People with BRCA Mutations following Risk-Reducing Bilateral Salpingo-Oophorectomy and the Role of Hormone Replacement Therapy: A Review.
Nitschke AS, Abreu do Valle H, Dawson L, Kwon JS, Hanley GE.
Cancers (Basel). 2023 Jan 24;15(3):711. doi: 10.3390/cancers15030711.
Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management.
McGee RB, Oak N, Harrison L, Xu K, Nuccio R, Blake AK, Mostafavi R, Lewis S, Taylor LM, Kubal M, Ouma A, Hines-Dowell SJ, Cheng C, Furtado LV, Nichols KE.
Clin Cancer Res. 2023 Jan 24:ccr.22.2482. doi: 10.1158/1078-0432.CCR-22-2482. Epub ahead of print.
Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China.
Nie J, Wu H, Sun L, Ding Y, Luan Y, Wu J.
Front Pharmacol. 2023 Jan 4;13:987337. doi: 10.3389/fphar.2022.987337.
Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China.
Nie J, Wu H, Sun L, Ding Y, Luan Y, Wu J.
Front Pharmacol. 2023 Jan 4;13:987337. doi: 10.3389/fphar.2022.987337.
Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan.
Nomura H, Abe A, Fusegi A, Yoshimitsu T, Misaka S, Murakami A, Matsumoto T, Tsumura S, Kanno M, Aoki Y, Netsu S, Omi M, Tanigawa T, Okamoto S, Omatsu K, Yunokawa M, Kanao H, Habano E, Arakawa H, Kaneko K, Ueki A, Haruyama Y, Inari H, Ueno T.
Sci Rep. 2023 Jan 19;13(1):1018. doi: 10.1038/s41598-023-28304-w.
The cancer-risk variant frequency among Polish population reported by the first national whole-genome sequencing study.
Mroczek M, Liu J, Sypniewski M, Pieńkowski T, Itrych B, Stojak J, Pronobis-Szczylik B, Stępień M, Kaja E, Dąbrowski M, Suchocki T, Wojtaszewska M, Zawadzki P, Mach A, Sztromwasser P, Król ZJ, Szyda J, Dobosz P.
Front Oncol. 2023 Jan 9;13:1045817. doi: 10.3389/fonc.2023.1045817.